Partnerships & Mergers

Lilly disclosed the decision as part of its second-quarter results, removing a phase 1/2 study of LY3884961 in Gaucher disease type 1 (GD1) from its pipeline.

Under the collaboration, Chugai scientists will use Biomni Lab to bring together AI capabilities and diverse biomedical resources within the company’s research environment.

Alteogen designed Hybrozyme to help convert biologic medicines that are traditionally administered through intravenous infusion into subcutaneous formulations.

Novo Nordisk will also use H1’s technology to support several aspects of clinical research, including trial design, patient enrollment and clinical trial site selection.

The companies will work together to generate pharmacological and bioanalytical data needed to advance NB4168 toward clinical development.

The test could also help clinicians identify patients who are unlikely to benefit from immunotherapy before treatment begins, potentially allowing them to consider alternative therapies sooner.

The partnership will unlock KSh10.4 billion (US$80 million) over the next five years to accelerate implementation of Kenya’s Every Woman Every Newborn Everywhere (EWENE) Acceleration Plan and support the country’s 90-90-80-80 maternal and newborn health targets.

Under the agreement, MiRecule will combine its NAVIgGator platform, which is designed to support the development of precision RNA medicines, with RBBL’s expertise in peptide discovery, development, and manufacturing.

Under the agreement, the companies will advance Sail’s lead programme, SAIL-0839, which is being developed to engineer CD4+ and CD8+ T-cells inside the body to treat immune-mediated diseases.

The partnership combines Budenheim’s manufacturing expertise with Brenntag’s biopharma services and distribution network.